{"id":11414,"date":"2025-08-20T11:01:11","date_gmt":"2025-08-20T11:01:11","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/11414\/"},"modified":"2025-08-20T11:01:11","modified_gmt":"2025-08-20T11:01:11","slug":"us-drug-pricing-shake-up-threatens-access-to-medicines-in-europe-politico","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/11414\/","title":{"rendered":"US drug pricing shake-up threatens access to medicines in Europe \u2013 POLITICO"},"content":{"rendered":"

For European drugmakers there are still many unknowns about how the MFN scheme \u2014 and overall tariffs<\/a> on pharmaceuticals \u2014 will play out.<\/p>\n

\u201cIt\u2019s too early to understand what is in scope, or the wider implication on Europe or member states,\u201d branded drugs lobby EFPIA told POLITICO, noting that the investigation is still ongoing. Yet it warned: \u201cImplementing MFN pricing could have an impact on jobs and our capacity to discover, develop and deliver new medicines for patients.\u201d<\/p>\n

EFPIA is lobbying Europe to make its own market more attractive to industry investment, saying it wants to see Europe \u201crethinking how we value innovation, significantly increasing what the region spends on innovative medicines and creating an operating environment which supports investment into research and early access to new medicines for patients.\u201d<\/p>\n

In the meantime, Swiss pharma company Roche said, \u201cA broad range of actions across European countries can contribute to retaining, sustaining, and developing the life sciences ecosystem,\u201d pointing to reducing clawbacks and other cost-containment measures as one example.<\/p>\n

For EU governments, the response may depend on how such pricing is implemented.\u00a0If it\u2019s tied to list prices, leaving net prices largely intact, stepping up procurement exercises might be enough. But if the worst case plays out \u2014 with net prices rising \u2014 governments could resort to budget caps and tighter access rules.<\/p>\n

In the meantime, the European Commission \u201cis closely monitoring the implementation of the U.S. Most Favoured Nation policy and any potential indirect effects on the European market,\u201d a Commission spokesperson wrote in response to a request for comment.\u00a0<\/p>\n

The EU\u2019s executive is \u201cin regular contact with the industry\u201d and \u201cis committed to maintaining the EU as an attractive location for research and development, including in rare diseases and other high-need areas,\u201d the spokesperson added.<\/p>\n","protected":false},"excerpt":{"rendered":"For European drugmakers there are still many unknowns about how the MFN scheme \u2014 and overall tariffs on…\n","protected":false},"author":2,"featured_media":11415,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[11020,1128,6929,6055,1820,10471,995,6930,11021,11022,382,11023,18,2427,2220,6621,135,475,1119,474,6904,19,4286,3536,2003,17,71,371,386,3544,7253,11024,188,11025,5790,11026,11027,3283,2554,11028,11029,2101,11030,172,11031,3439,11032,383,2423,1255,1997,384],"class_list":{"0":"post-11414","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-alexander-natz","9":"tag-australia","10":"tag-austria","11":"tag-belgium","12":"tag-benchmarks","13":"tag-budget","14":"tag-canada","15":"tag-companies","16":"tag-conflict","17":"tag-czech-republic","18":"tag-denmark","19":"tag-drug-pricing","20":"tag-eire","21":"tag-finland","22":"tag-france","23":"tag-germany","24":"tag-health","25":"tag-health-care","26":"tag-health-systems","27":"tag-healthcare","28":"tag-iceland","29":"tag-ie","30":"tag-industry","31":"tag-innovation","32":"tag-investment","33":"tag-ireland","34":"tag-israel","35":"tag-italy","36":"tag-japan","37":"tag-life-sciences","38":"tag-lithuania","39":"tag-luxembourg","40":"tag-markets","41":"tag-medicines","42":"tag-new-zealand","43":"tag-norway","44":"tag-patient-access","45":"tag-patients","46":"tag-pharma","47":"tag-procurement","48":"tag-public-affairs","49":"tag-public-health","50":"tag-rare-diseases","51":"tag-research","52":"tag-research-and-development","53":"tag-retail","54":"tag-slovenia","55":"tag-spain","56":"tag-switzerland","57":"tag-tariffs","58":"tag-trade","59":"tag-united-states"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/11414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=11414"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/11414\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/11415"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=11414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=11414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=11414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}